Revolution Medicines Stock Forecast

Stock Price Forecast

According to 24 analysts polled by S&P Global, Revolution Medicines stock has a consensus rating of "Strong Buy" and an average price target of $259.14. The average 1-year stock price forecast is 36.56% higher than the current stock price, while the lowest is $179 (-5.67%) and the highest is $320 (+68.63%).

Price Target: $259.14 (+36.56%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$179	$259.14	$260	$320
Change	-5.67%	+36.56%	+37.02%	+68.63%

Analyst Ratings

The average analyst rating for Revolution Medicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	May '26	Jun '26	Jul '26	Aug '26	Sep '26	Oct '26
Strong Buy	17	17	17	17	17	18
Buy	4	4	4	4	5	5
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	22	22	22	22	23	24

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Alec Stranahan Bank of America Securities	Bank of America Securities	Buy Maintains $265 → $264	Buy	Maintains	$265 → $264	+39.12%	Oct 9, 2026
Michael Schmidt Guggenheim	Guggenheim	Buy Maintains $275	Buy	Maintains	$275	+44.92%	Oct 9, 2026
Tyler Van Buren TD Cowen	TD Cowen	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Oct 8, 2026
Laura Prendergast Stifel Nicolaus	Stifel Nicolaus	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Oct 8, 2026
Leonid Timashev RBC Capital	RBC Capital	Buy Maintains $251 → $259	Buy	Maintains	$251 → $259	+36.49%	Oct 8, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

188.24M

Revenue Next Year

1.26B

from 188.24M

567.30%

from 188.24M

EPS This Year

-9.62

from -5.95

EPS Next Year

-5.72

from -9.62

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	29.39M	35.38M	11.58M	-	-	188.24M
Gross Profit	-157.56M	-217.69M	-407.86M	-592.23M	-987.33M	161.48M
Gross Margin	-536.09%	-615.30%	-3,522.14%	-	-	85.79%
Operating Income	-188.01M	-258.28M	-475.99M	-689.52M	-1.18B	-1.92B
Net Income	-187.09M	-248.71M	-436.37M	-600.09M	-1.13B	-2.02B
EPS	-	-	-	-	-5.95	-9.62
Free Cash Flow	-	-	-	-	-913.73M	-1.68B
No. Analysts	-	-	-	-	-	23

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	354.7M
Avg	188.2M
Low	n/a

Revenue Growth

Chart

Revenue Growth	2027	2028
High	1,175.0%
Avg	567.3%
Low	226.5%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-8.21
Avg	-9.62
Low	-12.30

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-